Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF
Status:
COMPLETED
Trial end date:
2024-01-10
Target enrollment:
Participant gender:
Summary
Objective To compare, in patients with Type 2 Diabetes Mellitus (T2DM) and Atrial Fibrillation (AF) undergoing radiofrequency ablation (RFA), whether strict weight management and glycemic control based on Glucagon-like Peptide-1 (GLP-1) receptor agonist treatment reduces the recurrence rate of atrial arrhythmias and rehospitalization rates for cardiac diseases compared to conventional post-procedural management (antiarrhythmic drugs and anticoagulants) and general antidiabetic drugs (excluding GLP-1 receptor agonists).
Study Design
This trial randomly divides participants into two groups:
The GLP-1 receptor agonist treatment-based strict weight management and glycemic control group.
The conventional treatment group
Phase:
NA
Details
Lead Sponsor:
Shanghai Chest Hospital
Collaborators:
Hefei Second People's Hospital The Second People's Hospital of Anhui Province The Third Affiliated Hospital of Anhui Medical University